Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection
Reads0
Chats0
TLDR
Given the high prevalence of chronic viral infections in patients who are candidates for anti-TNF therapy and the potential for these agents in the treatment of Chronic viral illness, additional studies are urgently needed to assess the risks and benefits of such therapy in these populations.Abstract:
Tumour necrosis factor α (TNFα) is a pivotal cytokine in host defences with broad ranging effects on the innate and adaptive immune systems. Clinically, TNFα inhibitors have demonstrated remarkable efficacy in a wide range of autoimmune and inflammatory disorders but clearly at the cost of heightened susceptibility to a variety of infections in those treated with these agents. Most reports to date have described increased susceptibility to intracellular pathogens in patients with underlying chronic viral infections, but little in the way of adverse event reporting in these patients has occurred. While the reported experience to date is rather limited, TNFα inhibitors have displayed a reasonable safety profile in the setting of some chronic viral infections and in certain circumstances have demonstrated adjunctive activity in the treatment of these infections. Given the high prevalence of chronic viral infections in patients who are candidates for anti-TNF therapy and the potential for these agents in the treatment of chronic viral illness, additional studies are urgently needed to assess the risks and benefits of such therapy in these populations.read more
Citations
More filters
Journal ArticleDOI
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
Jean-François Rahier,Fernando Magro,Candida Abreu,Alessandro Armuzzi,Shomron Ben-Horin,Yehuda Chowers,Mario Cottone,L. de Ridder,Glen A. Doherty,Robert Ehehalt,Maria Esteve,K.H. Katsanos,Charlie W. Lees,Eithne MacMahon,Tom G. Moreels,Walter Reinisch,Herbert Tilg,Lydjie Tremblay,Gigi Veereman-Wauters,N. Viget,Yazdan Yazdanpanah,Rami Eliakim,Jean-Frederic Colombel +22 more
TL;DR: The treatment of inflammatory bowel disease has been revolutionised over the past decade by the increasing use of immunomodulators, mainly azathioprine/6-mercaptopurine and methotrexate, together with the advent of biological therapy.
Journal ArticleDOI
Sarcopenia: Its assessment, etiology, pathogenesis, consequences and future perspectives
Yves Rolland,Stefan A. Czerwinski,G. Abellan Van Kan,John E. Morley,Matteo Cesari,Graziano Onder,Jean Woo,Richard N. Baumgartner,Fabien Pillard,Yves Boirie,Wm. Cameron Chumlea,Bruno Vellas +11 more
TL;DR: On-going and future clinical trials on sarcopenia may radically change the authors' preventive and therapeutic approaches of mobility disability in older people.
Journal ArticleDOI
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Daniel E. Furst,E.C. Keystone,J. Braun,F. C. Breedveld,G.-R. Burmester,F De Benedetti,Thomas Dörner,Paul Emery,Roy Fleischmann,Allan Gibofsky,Joachim R. Kalden,A. Kavanaugh,Bruce Kirkham,Philip J. Mease,J. Sieper,Nora G. Singer,Josef S Smolen,P.L.C.M. van Riel,Michael H. Weisman,Kevin L. Winthrop +19 more
TL;DR: The consensus statement is annotated to document the credibility of the data supporting it as much as possible and the number of possible references has become so large that reviews are sometimes included; if they contain category A references, they will be referred to as category A evidence.
Journal ArticleDOI
British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005.
Catherine H. Smith,Alexander Vincent Anstey,Jonathan N.W.N. Barker,A. D. Burden,R. J. G. Chalmers,David Chandler,Andrew Yule Finlay,C. E. M. Grifitths,K Jackson,Neil McHugh,K.E. McKenna,Nick J. Reynolds,Anthony Ormerod +12 more
TL;DR: Two biological therapies, etanercept (Enbrel) and efalizumab (Raptiva) were licensed in 2004 in the U.K. for patients with moderate to severe psoriasis and have emerged over the last 3–5 years as potentially valuable alternative therapeutic options.
Journal ArticleDOI
Proinflammatory Signaling Regulates Hematopoietic Stem Cell Emergence
Raquel Espín-Palazón,Raquel Espín-Palazón,David L. Stachura,Clyde Campbell,Diana García-Moreno,Natasha Del Cid,Albert D. Kim,Sergio Candel,José Meseguer,Victoriano Mulero,David Traver +10 more
TL;DR: It is demonstrated that proinflammatory signaling, in the absence of infection, is utilized by the developing embryo to generate the lineal precursors of the adult hematopoietic system.
References
More filters
Journal ArticleDOI
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
Frank J. Palella,Kathleen M. Delaney,Anne C. Moorman,Mark O. Loveless,Jack Fuhrer,Glen A. Satten,Diane J. Aschman,Scott D. Holmberg +7 more
TL;DR: The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.
Journal ArticleDOI
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
TL;DR: A random-primed complementary DNA library was constructed from plasma containing the uncharacterized non-A, non-B hepatitis agent and screened with serum from a patient diagnosed with NANBH, showing consistent with the agent being similar to the togaviridae or flaviviridae.
Journal ArticleDOI
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Michael W. Fried,Mitchell L. Shiffman,K. Rajender Reddy,C. Smith,George Marinos,Fernando L. Gonçales,Dieter Häussinger,Moisés Diago,Giampiero Carosi,Daniel Dhumeaux,Antonio Craxì,A. Lin,Joseph Hoffman,Jian Yu +13 more
TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Journal ArticleDOI
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei Hsiu Ling,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
Journal ArticleDOI
Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
TL;DR: A study was conducted to evaluate the impact of protease inhibitors on the rates of selected opportunistic processes and mortality in patients with AIDS and found similar results.